VOR — Vor Biopharma Income Statement
0.000.00%
Last trade - 00:00- $116.65m
- -$20.53m
- 13
- 38
- 23
- 14
Annual income statement for Vor Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10.4 | 43.4 | 69 | 93.4 | 126 |
| Operating Profit | -10.4 | -43.4 | -69 | -93.4 | -126 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
| Net Income After Taxes | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.6 | -49.3 | -70.1 | -92.1 | -118 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.354 | -1.38 | -2.1 | -2.33 | -1.75 |
| Dividends per Share |